Record Sales in March for New Zealand

Rua Bioscience is pleased to provide the following business update, highlighting positive sales performance across New Zealand, Australia, and Germany.

New Zealand – Record month

March marked a significant milestone in Rua’s home market, with the company achieving its highest-ever monthly sales in New Zealand. This performance is more than a company milestone – it’s a strong signal that Rua is not only increasing its market share, but that the overall medicinal cannabis market is expanding.

Australia: Record Flower Sales Reflect Deepening Market Presence

Australia also delivered a record month, with Rua achieving its highest-ever unit sales of key medicinal cannabis flower product lines. This strong result reflects the company’s consistent presence in the Australian market, backed by growing relationships with prescribers, distributors, and patients. Rua continues to view Australia as a strategically important growth opportunity and is investing in strengthening its commercial footprint.

Germany: High Demand

In Germany, demand for Rua’s products remains strong. Current sales are temporarily limited by a supply shortage to meet our increased demand, Rua expects growth to resume as the supply chain capacity is restored over the next quarter. The German market remains a core focus for the company’s international expansion strategy.

Rua's continued focus on quality, accessible products is resonating with patients and prescribers alike. With new product launches planned in the coming months, Rua is well positioned to maintain and accelerate this growth trajectory. The company is proud to be a key player in shaping the future of medicinal cannabis in Aotearoa New Zealand.

Rua Bioscience looks forward to keeping shareholders updated as we continue this positive growth trajectory and unlock new opportunities.

ENDS  
 
The person who authorised this announcement:

Paul Naske
Chief Executive Officer
[email protected]
+64 21 445154

---

Announcement PDF